Physician profile
Gilbert Bader
NPI 1568800738
$2,177.85
in general payments reported to CMS, 2019-2025
32 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,741 · 2020: $267 · 2021: $39.78 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $341.79 | 2019 | |
| Amgen INC. | $338.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $239.90 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $149.78 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $130.50 | 2025 | |
| Incyte Corporation | $123.91 | 2019-2020 | |
| Celgene Corporation | $118.86 | 2019 | |
| Genzyme Corporation | $89.92 | 2019-2021 | |
| Eisai INC. | $83.20 | 2020 | |
| Alexion Pharmaceuticals, INC. | $77.88 | 2019 | |
| Lilly USA, LLC | $57.63 | 2019-2020 | |
| Pfizer INC. | $49.66 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $46.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.26 | 2019-2020 | |
| Seagen INC. | $28.09 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.32 | 2019 | |
| Puma Biotechnology, INC. | $22.75 | 2019 | |
| Astellas Pharma US INC | $21.24 | 2020 | |
| Eusa Pharma (US) LLC | $20.29 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $16.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.35 | 2020 | |
| Blueprint Medicines Corporation | $15.78 | 2020 | |
| Csl Behring | $15.63 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.28 | 2020 | |
| Daiichi Sankyo INC. | $14.31 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.36 | 2019 | |
| Glaxosmithkline, LLC. | $12.38 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.03 | 2020 | |
| Exelixis INC. | $11.75 | 2019 | |
| Servier Pharmaceuticals LLC | $10.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilbert Bader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.